<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Firefly Neuroscience, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/firefly-neuroscience-inc</link>
    <description>Latest news and press releases for Firefly Neuroscience, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 26 Mar 2026 11:45:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/firefly-neuroscience-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835448b78dffbe2df0e22fd.webp</url>
      <title>Firefly Neuroscience, Inc.</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc</link>
    </image>
    <item>
      <title>Firefly Confirms Public-Private Partnership with the Department of War</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-confirms-public-private-partnership-with-the-department-of-war</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-confirms-public-private-partnership-with-the-department-of-war</guid>
      <pubDate>Thu, 26 Mar 2026 11:45:00 GMT</pubDate>
      <description>Firefly’s AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members Partnership Represents a Significant Expansion of Company’s Commercial Footprint into the U.S. Government and Defense Health Sectors KENMORE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (NASDAQ: AIFF) (“Firefly,” or the “Company”), today announced a partnership with the Department of War (“DoW”) to support the assessment and tr</description>
    </item>
    <item>
      <title>Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-announces-discovery-of-new-brain-wave-biomarkers-for-differential-diagnosis-of-adhd-80</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-announces-discovery-of-new-brain-wave-biomarkers-for-differential-diagnosis-of-adhd-80</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Over 22 million Americans are diagnosed with ADHD — yet an objective biological marker for distinguishing between its three distinct subtypes has, to date,</description>
    </item>
    <item>
      <title>Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-progresses-toward-development-and-commercial-launch-of-its-foundation-model-of-the-human-brain-powered-by-nvidia-gpu-acceleration-7</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-progresses-toward-development-and-commercial-launch-of-its-foundation-model-of-the-human-brain-powered-by-nvidia-gpu-acceleration-7</guid>
      <pubDate>Wed, 04 Mar 2026 12:45:00 GMT</pubDate>
      <description>- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes - - Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain - KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company</description>
    </item>
    <item>
      <title>Firefly Neuroscience Reports Third Quarter 2025 Financial Results</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-reports-third-quarter-124500087</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-reports-third-quarter-124500087</guid>
      <pubDate>Wed, 12 Nov 2025 12:45:00 GMT</pubDate>
      <description>– Quarterly performance characterized by higher revenues, reduced cost structure and improved bottom line – – Successful business integration drives 10.9% sequential quarter-over-quarter EEG/ERP scan volumes and 30% sequential revenue growth – KENMORE, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental d</description>
    </item>
    <item>
      <title>Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-partners-healingmaps-offer-115500249</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-partners-healingmaps-offer-115500249</guid>
      <pubDate>Fri, 05 Sep 2025 11:55:00 GMT</pubDate>
      <description>KENMORE, N.Y. and MIAMI, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a new partnership with HealingMaps, the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (“TMS”) clinics, and Advanced Behavioral Strategies (ABS). The coll</description>
    </item>
    <item>
      <title>Firefly Neuroscience Successfully Deploys NVIDIA L40S GPU Acceleration to Power Next-Gen ‘CLEAR’ Platform</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-successfully-deploys-nvidia-114500643</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-successfully-deploys-nvidia-114500643</guid>
      <pubDate>Tue, 26 Aug 2025 11:45:00 GMT</pubDate>
      <description>– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just months after Firefly announced its acceptance into the NVIDIA Connect Program – KENMORE, Wash. and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain he</description>
    </item>
    <item>
      <title>Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-inks-latest-commercial-agreement-114500578</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-inks-latest-commercial-agreement-114500578</guid>
      <pubDate>Mon, 14 Jul 2025 11:45:00 GMT</pubDate>
      <description>– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain’s functional architecture in rare genetic conditions – – Building and growing a license business is an increasingly important pillar of Firefly’s commercial strategy – KENMORE, N.Y., July 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) compa</description>
    </item>
    <item>
      <title>Stran &amp; Company Appoints Veteran Financial Executive Brian M. Posner to  its Board of Directors</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/stran-and-company-appoints-veteran-financial-executive-brian-m-posner-to-its-board-of-directors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/stran-and-company-appoints-veteran-financial-executive-brian-m-posner-to-its-board-of-directors-1</guid>
      <pubDate>Thu, 10 Jul 2025 12:00:00 GMT</pubDate>
      <description>Mr. Posner will serve as Chairman of the Audit CommitteeQuincy, MA, July 10, 2025 (GLOBE NEWSWIRE) -- Stran &amp; Company, Inc. (“Stran” or the “Company”) (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading provider of outsourced marketing solutions specializing in promotional products and loyalty incentives, today announced the appointment of Brian M. Posner, MBA, to its Board of Directors. Mr. Posner will serve as Chairman of the Audit Committee. Brian Posner brings over four decades of public company finan</description>
    </item>
    <item>
      <title>Firefly Neuroscience to be Added to the Russell Microcap® Index</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-added-russell-microcap-120500377</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-added-russell-microcap-120500377</guid>
      <pubDate>Mon, 23 Jun 2025 12:05:00 GMT</pubDate>
      <description>– Comes less than a year after listing on Nasdaq – KENMORE, N.Y., June 23, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that it will be added to the Russell Microcap® Index as part of this year’s reconstitution. The additions will be made effective after the U.S. market</description>
    </item>
    <item>
      <title>Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-researchers-uncover-powerful-114500760</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-researchers-uncover-powerful-114500760</guid>
      <pubDate>Fri, 20 Jun 2025 11:45:00 GMT</pubDate>
      <description>– Research supports combined use of EEG/ERP and vMRI for accurate differential diagnosis of SCD, MCI and dementia – – Also highlights that low-cost and off-based EEG/ERP alone also delivered reasonably accurate predictions of cognitive impairment typology – – Underscores the value of recent Evoke acquisition that builds upon Firefly&apos;s FDA-cleared BNA™ AI platform and unique integrated normative reference group – – It’s well accepted that earlier dementia course detection can improve outcomes and</description>
    </item>
    <item>
      <title>Correction From Source: Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/correction-source-firefly-neuroscience-achieves-010000913</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/correction-source-firefly-neuroscience-achieves-010000913</guid>
      <pubDate>Tue, 06 May 2025 01:00:00 GMT</pubDate>
      <description>A correction from source is being issued with respect to the press release titled, Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc., released on May 5, 2025 at 8:00 am ET. Please note, the correct form of payment of the potential Evoke investors’ earn-out is in Firefly’s common stock. The complete corrected press release follows: Builds upon Firefly’s recent acceptance into the NVIDIA Connect progr</description>
    </item>
    <item>
      <title>Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-achieves-multi-fold-114500305</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-achieves-multi-fold-114500305</guid>
      <pubDate>Mon, 05 May 2025 11:45:00 GMT</pubDate>
      <description>Builds upon Firefly’s recent acceptance into the NVIDIA Connect program Marks next major step toward building a proprietary foundation model of the human brain KENMORE, N.Y., May 05, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce its acquisition of Evoke Neuroscie</description>
    </item>
    <item>
      <title>Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-announces-exercise-warrants-130000897</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-announces-exercise-warrants-130000897</guid>
      <pubDate>Fri, 21 Feb 2025 13:00:00 GMT</pubDate>
      <description>Extends cash runway well into mid-2026; no new/replacement warrants issuedKENMORE, N.Y., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announced that it has received total proceeds of $8,824,710 from the exercise of warrants to purchase 823,530 shares of the comm</description>
    </item>
    <item>
      <title>Firefly Neuroscience Announces Publications Demonstrating the Utility of Advanced EEG Analytics in Drug Development and Neuropsychiatric Care</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-announces-publications-demonstrating-the-utility-of-advanced-eeg-analytics-in-drug-development-and-neuropsychiatric-care</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-announces-publications-demonstrating-the-utility-of-advanced-eeg-analytics-in-drug-development-and-neuropsychiatric-care</guid>
      <pubDate>Fri, 24 Jan 2025 05:00:00 GMT</pubDate>
      <description>Growing body of clinical evidence supports use of Company’s FDA-Cleared BNA™ platform to provide objective measures of drug efficacy and cognitive change,</description>
    </item>
    <item>
      <title>Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-discovers-breakthrough-cognitive-brain-age-biomarker-using-its-fda-cleared-bnatm-platform</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-discovers-breakthrough-cognitive-brain-age-biomarker-using-its-fda-cleared-bnatm-platform</guid>
      <pubDate>Tue, 14 Jan 2025 05:00:00 GMT</pubDate>
      <description>Measuring brain age with EEG and BNA™ could lead to a proactive and scalable approach to early screening for Alzheimer&amp;apos;s patients KENMORE, N.Y., Jan. 14,</description>
    </item>
    <item>
      <title>Firefly Neuroscience Closes on Financing of up to $12.4 Million</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-closes-on-financing-of-up-to-dollar124-million</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-closes-on-financing-of-up-to-dollar124-million</guid>
      <pubDate>Tue, 31 Dec 2024 05:00:00 GMT</pubDate>
      <description>TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”)</description>
    </item>
    <item>
      <title>Firefly Neuroscience Appoints Current Board Member, Greg Lipschitz, as Executive Chairman</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-appoints-current-board-member-greg-lipschitz-as-executive-chairman</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-appoints-current-board-member-greg-lipschitz-as-executive-chairman</guid>
      <pubDate>Wed, 04 Dec 2024 05:00:00 GMT</pubDate>
      <description>TORONTO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”)</description>
    </item>
    <item>
      <title>Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-reports-third-quarter-2024-results-and-provides-stockholder-update</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-reports-third-quarter-2024-results-and-provides-stockholder-update</guid>
      <pubDate>Thu, 14 Nov 2024 05:00:00 GMT</pubDate>
      <description>Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds</description>
    </item>
    <item>
      <title>Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-announces-inducement-grant-under-nasdaq-listing-rule-5635c4</guid>
      <pubDate>Fri, 25 Oct 2024 04:00:00 GMT</pubDate>
      <description>TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company</description>
    </item>
    <item>
      <title>Firefly Neuroscience Announces Use of Its Brain Network Analytics Platform in Phase 1 Study of SP-624, the First Potential Treatment Designed for Women with Major Depressive Disorder</title>
      <link>https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-announces-use-of-its-brain-network-analytics-platform-in-phase-1-study-of-sp-624-the-first-potential-treatment-designed-for-women-with-major-depressive-disorder</link>
      <guid isPermaLink="true">https://6ix.com/company/firefly-neuroscience-inc/news/firefly-neuroscience-announces-use-of-its-brain-network-analytics-platform-in-phase-1-study-of-sp-624-the-first-potential-treatment-designed-for-women-with-major-depressive-disorder</guid>
      <pubDate>Tue, 15 Oct 2024 04:00:00 GMT</pubDate>
      <description>Study to Leverage Firefly’s BNA™ Technology for Biomarker Identification, with Potential Applications for Broader Neurological Research TORONTO, Oct. 15, 2024</description>
    </item>
  </channel>
</rss>